Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT00811889 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Type 2 Diabetes
Diabetic Nephropathy

Interventions

OTHER: Placebo
DRUG: Bardoxolone Methyl (RTA 402)

Sponsor

Biogen